1. English JF, Cundiff MY, Malone JD, et al. Bioterrorism Readiness Plan: A Template for Healthcare Facilities. Washington, DC: Association for Professionals in Infection Control and Epidemiology; 1999.

2. Ready.gov. Biohazard Exposure. Available at https://www.ready.gov/biohazard. Last accessed August 16, 2023.

3. Placer County Health and Human Services and Placer/Nevada County Medical Society. Zebra Primer on Bioterrorism. Auburn, CA: Placer County Health and Human Services; 2001.

4. Crutcher M. Response to biological terrorism. Paper presented at: Epidemiologists and Professionals in Infection Control (EPIC) Meeting; May 2000, Oklahoma City, OK.

5. Federal Bureau of Investigation. Amerithrax or Anthrax Investigation. Available at https://archives.fbi.gov/archives/about-us/history/famous-cases/anthrax-amerithrax. Last accessed August 16, 2023.

6. Office of the Assistant Secretary of Defense. DoD News Briefing. Proliferation: Threat and Response Briefing. Available at https://irp.fas.org/threat/prolif97/t11251997_t1125ptr.html. Last accessed August 16, 2023.

7. Centers for Disease Control and Prevention. Bioterrorism Agents/Diseases. Available at https://emergency.cdc.gov/agent/agentlist-category.asp. Last accessed August 16, 2023.

8. Audi J, Belson M, Patel M, Schier J, Osterloh J. Ricin poisoning: a comprehensive review. JAMA. 2005;294(18):2342-2351.

9. Dembek ZF, Alves DA, Cieslak TJ, et al. (eds). USAMRIID's Medical Management of Biological Casualties Handbook. 7th ed. Fort Detrick, MD: U.S. Army Medical Research; 2011.

10. Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci USA. 2005;102(28):9984-9989.

11. Dembek ZF. Medical Aspects of Biological Warfare. Washington, DC: TMM Publications; 2007.

12. Weber DJ, Sickbert-Bennett E, Gergen MF, Rutala WA. Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands. JAMA. 2003;289(10):1274-1277.

13. Centers for Disease Control and Prevention. Anthrax. The Threat of an Anthrax Attack. Available at https://www.cdc.gov/anthrax/bioterrorism/threat.html. Last accessed August 16, 2023.

14. Katzman K. Iraq: Weapons Programs, Compliance, and U.S. Policy. Available at https://digital.library.unt.edu/ark:/67531/metacrs4231/m1/1/high_res_d/IB92117_2003Mar26.pdf. Last accessed August 16, 2023.

15. Inglesby TV, O'Toole T, Henderson DA, et al.; Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287(17):2236-2252.

16. Centers for Disease Control and Prevention. What is Anthrax? Types of Anthrax. Available at https://www.cdc.gov/anthrax/basics/index.html. Last accessed August 16, 2023.

17. Bower WA, Schiffer J, Atmar RL, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2019. MMWR. 2019;68(4):1-14.

18. Centers for Disease Control and Prevention. Travelers' Health. CDC Yellow Book. Table of Contents. Section 5: Travel-Associated Infections and Diseases - Bacterial. Available at https://wwwnc.cdc.gov/travel/yellowbook/2024/table-of-contents. Last accessed August 16, 2023.

19. Centers for Disease Control and Prevention. Travelers' Health: Anthrax. CDC Yellow Book 2024. Available at https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/anthrax#agent. Last accessed August 16, 2023.

20. Johnson S. Response to bioterrorism: the role of laboratories. Paper presented at: Epidemiologists and Professionals in Infection Control (EPIC) Meeting; August 17, 2000; Oklahoma City, OK.

21. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis. 2008;14(4):e1.

22. Centers for Disease Control and Prevention. Anthrax: Recommended Specimens for Microbiology and Pathology for Diagnosis of Anthrax. Available at https://www.cdc.gov/anthrax/specificgroups/lab-professionals/recommended-specimen.html. Last accessed August 16, 2023.

23. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2):e130687.

24. Centers for Disease Control and Prevention. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident: recommendations and reports. MMWR. 2015;64(RR4):1-28.

25. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR. 2001;50(42):909-919.

26. Jang KH, Nam S-J, Locke JB, et al. Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete. Angew Chem Int Ed Engl. 2013;52(30):7822-7824.

27. Barclay L. Anthrax Guidelines Address Nonpregnant, Pregnant Adults. Available at https://www.medscape.com/viewarticle/819274. Last accessed August 16, 2023.

28. Alexander JJ, Colangelo PM, Cooper CK, Roberts R, Rodriguez WJ, Murphy MD. Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations. Pediatr Infect Dis J. 2008;27(11):955-957.

29. U.S. Food and Drug Administration. FDA Approves Treatment for Inhalation Anthrax. Available at https://wayback.archive-it.org/7993/20170405005211/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm. Last accessed August 16, 2023.

30. Advisory Committee on Immunization Practices. Notice to readers: use of anthrax vaccine in the response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR. 2002;51(45):1024-1026.

31. Centers for Disease Control and Prevention. Considerations for Anthrax Vaccine Adsorbed (AVA) Post-Exposure Prioritization Final. Available at https://www.cdc.gov/anthrax/pdf/ava-post-event-prioritization-guidance.pdf. Last accessed August 16, 2023.

32. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. JAMA. 2000;283(17):2281-2290.

33. Centers for Disease Control and Prevention. Emergency Preparedness and Response. Plague (Yersinia pestis). Available at https://emergency.cdc.gov/agent/plague/publications-training.asp. Last accessed August 16, 2023.

34. Centers for Disease Control and Prevention. Plague. Available at https://www.cdc.gov/plague. Last accessed August 16, 2023.

35. Wheelis M. Biological warfare at the 1346 siege of Caffa. Emerg Infect Dis. 2002;8(9):971-975.

36. Centers for Disease Control and Prevention. Frequently Asked Questions about Plague. Available at https://emergency.cdc.gov/agent/plague/faq.asp. Last accessed August 16, 2023.

37. Heymann DL (ed). Control of Communicable Disease Manual. 20th ed. Washington, DC: American Public Health Association; 2014.

38. Centers for Disease Control and Prevention. Plague: Diagnosis and Evaluation. Available at https://emergency.cdc.gov/agent/plague/diagnosis.asp. Last accessed August 16, 2023.

39. Centers for Disease Control and Prevention. Plague: Resources for Clinicians. Available at https://www.cdc.gov/plague/healthcare/clinicians.html. Last accessed August 16, 2023.

40. Sha J, Endsley JJ, Kirtley ML, et al. Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks. J Clin Microbiol. 2011;49(5):1708-1715.

41. Friedlander AM, Welkos SL, Worsham PL, et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis. 1995;21(Suppl 2):S178-S181.

42. Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. MMWR. 2021;70(3):1-27.

43. Boulanger LL, Ettestad P, Fogarty JD, et al. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in New Mexico, 1985–1999. Clin Infect Dis. 2004;38:663-669.

44. Centers for Disease Control and Prevention. Responding to a Plague Bioterrorism Event. Available at https://www.cdc.gov/plague/healthcare/bioterrorism-response.html. Last accessed August 16, 2023.

45. Jefferson T, Demicheli V, Pratt M. Vaccines for preventing plague. Cochrane Database Syst Rev. 2000(2):CD000976.

46. Price JL, Manetz TS, Shearer JD, House RV. Preclinical safety assessment of a recombinant plague vaccine (rF1V). Int J Toxicol. 2013;32(5):327-335.

47. Biryukov S, Dankmeyer JL, Shamsuddin Z, et al. Impact of toll-like receptor-specific agonists on the host immune response to the Yersinia pestis plague rF1V vaccine. Front Immunol. 2021;12:726416.

48. Global Biodefense. FDA Grants Orphan Drug Designation for Plague Vaccine. Available at https://globalbiodefense.com/2017/03/10/fda-grants-orphan-drug-designation-plague-vaccine/. Last accessed August 16, 2023.

49. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763-2773.

50. Centers for Disease Control and Prevention. Key Facts About Tularemia. Available at https://emergency.cdc.gov/agent/tularemia/facts.asp. Last accessed August 16, 2023.

51. World Health Organization. Health Aspects of Chemical and Biological Weapons: Report of a WHO Group of Consultants. Geneva: World Health Organization; 1970.

52. Sacramento County Public Health Division. Medical Treatment and Response to Suspected Tularemia: Information for Health Care Providers During Biologic Emergencies. Available at https://dhs.saccounty.net/PUB/Documents/PUB_ZTularemia.pdf. Last accessed August 16, 2023.

53. Cleveland KO. Tularemia. Available at https://emedicine.medscape.com/article/230923-overview. Last accessed August 16, 2023.

54. Penn RL. Francisella tularensis (tularemia). In: Bennet JE, Dolin R, Blaser MJ (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. New York, NY: Saunders; 2014: 2060-2068.

55. County of Los Angeles Department of Public Health and the Emergency Medical Services Agency of the Los Angeles County Department of Health Services. Terrorism Agent Information and Treatment Guidelines for Clinicians and Hospitals. Los Angeles, CA: County of Los Angeles Public Health; 2012.

56. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Cin Infect Dis. 2014;59(2):e10-e52.

57. LexiComp Online. Available at https://online.lexi.com. Last accessed August 16, 2023.

58. Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the United States. Arch Neurol. 2009;66(4):523-527.

59. Lamps LW, Havens JM, Sjostedt A, Page DL, Scott MA. Histologic and molecular diagnosis of tularemia: a potential bioterrorism agent endemic to North America. Mod Pathol. 2004;17(5):489-495.

60. French GR, Plotkin SA. Miscellaneous limited-use vaccines. In: Plotkin S, Orenstein W, Offit PA (eds). Vaccines. 6th ed. Philadelphia, PA: Saunders; 2012: 728-733.

61. Oyston PCF, Quarry JE. Tularemia vaccine: past, present, and future. Antoine van Leeuwenhoek. 2005;87(4):277-281.

62. Meyer H, Ehmann R, Smith GL. Smallpox in the post-eradication era. Viruses. 2020;12(2):138.

63. Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann Intern Med. 1997;127(8):635-642.

64. Dowd GE. War Under Heaven: Pontiac, the Indian Nations, & the British Empire. Baltimore, MD: Johns Hopkins University Press; 2004.

65. Brennan JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med. 2002;346(17):1300-1308.

66. Centers for Disease Control and Prevention. Smallpox: Diagnosis and Evaluation. Available at https://www.cdc.gov/smallpox/clinicians/diagnosis-evaluation.html. Last accessed August 16, 2023.

67. Alibek K, Handelman S. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World. New York, NY: Random House; 1999.

68. Fenner F, Henderson DA, Arita A, Jezek Z, Ladnyl ID. Smallpox and its Eradication. Geneva: World Health Organization; 1988.

69. Centers for Disease Control and Prevention. Acute, Generalized Vesicular or Pustular Rash Illness Protocol in the United States. Available at https://www.cdc.gov/smallpox/pdfs/rash-illness-protocol.pdf. Last accessed August 16, 2023.

70. Hussain AN. Smallpox. Available at https://emedicine.medscape.com/article/237229-overview. Last accessed August 16, 2023.

71. Centers for Disease Control and Prevention. Smallpox: Detection and Response. Available at https://www.cdc.gov/smallpox/bioterrorism/public/detection-response.html. Last accessed August 16, 2023.

72. Texas Department of Health. Emergency Preparedness and Response. Available at https://www.texascountyhealth.org/emergency-preparedness. Last accessed August 16, 2023.

73. Centers for Disease Control and Prevention. Specimen Collection and Transport Guidelines for Suspect Smallpox Cases. Available at https://www.cdc.gov/smallpox/lab-personnel/specimen-collection/specimen-collection-transport.html. Last accessed August 16, 2023.

74. World Health Organization. Smallpox. Available at https://www.who.int/health-topics/smallpox#tab=tab_1. Last accessed August 16, 2023.

75. Centers for Disease Control and Prevention. Smallpox: Vaccine Basics. Available at https://www.cdc.gov/smallpox/vaccine-basics/index.html. Last accessed August 16, 2023.

76. Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections. Viruses. 2010;2(12):2740-2762.

77. U.S. Food and Drug Administration. FDA Approves the First Drug with an Indication for Treatment of Smallpox. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox. Last accessed August 16, 2023.

78. Grosenbach DW, Honeychurch K, Rose E, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44-53.

79. Centers for Disease Control and Prevention. Smallpox. Medical Management of Adverse Reactions to Vaccinia Virus Vaccination. Available at https://www.cdc.gov/smallpox/clinicians/vaccine-medical-management6.html. Last accessed August 16, 2023.

80. MedlinePlus. Cidofovir Injection. Available at https://medlineplus.gov/druginfo/meds/a696037.html. Last accessed August 16, 2023.

81. University of Maryland Medical Center. Important Information About Vaccinia (Smallpox) Vaccine. Available at https://health.umd.edu/sites/default/files/inline-files/Important%20Information%20About%20Vaccinia%20%28Smallpox%29%20Vaccine.pdf. Last accessed August 16, 2023.

82. U.S. Food and Drug Administration. Smallpox. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/smallpox. Last accessed August 16, 2023.

83. Hatch GJ, Graham VA, Bewley KR, et al. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol. 2013;87(14):7805-7815.

84. U.S. Food and Drug Administration. ACAM2000 (Smallpox Vaccine) Questions and Answers. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000-smallpox-vaccine-questions-and-answers. Last accessed August 16, 2023.

85. Fierce Pharma. Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE Smallpox Vaccine to the U.S. Strategic National Stockpile. Available at https://www.fiercepharma.com/vaccines/bavarian-nordic-completes-delivery-of-20-million-doses-of-imvamune%C2%AE-smallpox-vaccine-to-u.Last accessed August 16, 2023.

86. Centers for Disease Control and Prevention. Smallpox. Vaccination Information. Available at https://www.cdc.gov/smallpox/clinicians/vaccination.html. Last accessed August 16, 2023.

87. U.S. Food and Drug Administration. FDA Approves First Live, Non-Replicating Vaccine to Prevent Smallpox and Monkeypox. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox. Last accessed August 16, 2023.

88. Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR. 2015;64(RR02):1-26.

89. Centers for Disease Control and Prevention. Smallpox: Ring Vaccination. Available at https://www.cdc.gov/smallpox/bioterrorism-response-planning/public-health/ring-vaccination.html. Last accessed August 16, 2023.

90. Borio L, Inglesby TV, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management.JAMA. 2002;287(18):2391-2405.

91. U.S. Army Medical Research and Materiel Command. Treatment of Viral Hemorrhagic Fevers with Intravenous Ribavirin in Military Treatment Facilities. Available at https://clinicaltrials.gov/ct2/show/NCT00992693. Last accessed August 16, 2023.

92. World Health Organization. Ribavirin: General Description. Available at https://list.essentialmeds.org/medicines/473. Last accessed August 16, 2023.

93. Cheng HY, French CE, Salam AP, et al. Lack of evidence for ribavirin treatment of lassa fever in systematic review of published and unpublished studies. Emerg Infect Dis. 2022;28(8):1559-1568.

94. Centers for Disease Control and Prevention. Viral Hemorrhagic Fevers: Testing for VHFs. Available at https://www.cdc.gov/vhf/abroad/healthcare-workers/specimens.html. Last accessed August 16, 2023.

95. Centers for Disease Control and Prevention. Division of High-Consequence Pathogens and Pathology. Submitting Specimens to CDC's Viral Special Pathogens Branch. Available at https://www.cdc.gov/ncezid/dhcpp/vspb/specimens.html. Last accessed August 16, 2023.

96. Racsa LD, Kraft CS, Olinger GG, Hensley LE. Viral hemorrhagic fever diagnostics. Clin Infect Dis. 2016;62(2):214-219.

97. Centers for Disease Control and Prevention. Interim Guidance for Managing Patients with Suspected Viral Hemorrhagic Fever in U.S. Hospitals. Available at https://www.cdc.gov/hai/pdfs/bbp/vhfinterimguidance05_19_05.pdf. Last accessed August 16, 2023.

98. U.S. Food and Drug Administration. For Physicians: How to Request Single Patient Expanded Access ("Compassionate Use"). Available at https://www.fda.gov/drugs/investigational-new-drug-ind-application/physicians-how-request-single-patient-expanded-access-compassionate-use. Last accessed August 16, 2023.

99. California Department of Industrial Relations, Division of Occupational Safety and Health. Interim Guidance on Ebola Virus. Available at https://www.dir.ca.gov/dosh/documents/Cal-OSHA-Guidance-on-Ebola-Virus.pdf. Last accessed August 16, 2023.

100. Centers for Disease Control and Prevention. Guidance on Personal Protective Equipment (PPE) To Be Used By Healthcare Workers during Management of Patients with Confirmed Ebola or Persons under Investigation (PUIs) for Ebola who are Clinically Unstable or Have Bleeding, Vomiting, or Diarrhea in U.S. Healthcare Settings, Including Procedures for Donning and Doffing PPE. Available at https://www.cdc.gov/vhf/ebola/healthcare-us/ppe/guidance.html. Last accessed August 16, 2023.

101. Public Health Agency of Canada. Clostridium botulinum. Available at https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/clostridium-botulinum.html. Last accessed August 16, 2023.

102. Frantz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278(5):399-411.

103. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA. 1997;278(5):433-435.

104. Alguire P (ed). ACP bioterrorism resource guide. ACP Observer. 2004;5.

105. Villar RG, Elliott SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am. 2006;20(2):313-327.

106. Centers for Disease Control and Prevention. Botulism: Information for Health Professionals. Available at https://www.cdc.gov/botulism/health-professional.html. Last accessed August 16, 2023.

107. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical guidelines for diagnosis and treatment of botulism, 2021. MMWR. 2021;70(2):1-30.

108. Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR. 2010;59(10):299.

109. U.S. Food and Drug Administration. FDA Approves First Botulinum Antitoxin for Use in Neutralizing All Seven Known Botulinum Nerve Toxin Serotypes. Available at https://wayback.archive-it.org/7993/20161022134538/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm. Last accessed August 16, 2023.

110. Varma JK, Katsitadze G, Moiscrafishvili M, et al. Signs and symptoms predictive of death in patients with foodborne botulism—Republic of Georgia, 1980–2002. Clin Infect Dis. 2004;39(3):357-362.

111. Centers for Disease Control and Prevention. Investigation of a ricin-containing envelope at a postal facility—South Carolina, 2003. MMWR. 2003;52(46):1129-1131.

112. Shea D, Gottron F. CRS Report for Congress. Ricin: Technical Background and Possible Role in Terrorism. Washington, DC: Library of Congress; 2004.

113. Centers for Disease Control and Prevention. Health Advisory: CDC Alert on Ricin. Available at https://emergency.cdc.gov/agent/ricin/han_022008.asp. Last accessed August 16, 2023.

114. Centers for Disease Control and Prevention. Ricin: Epidemiological Overview for Clinicians. Available at https://emergency.cdc.gov/agent/ricin/clinicians/epidemiology.asp. Last accessed August 16, 2023.

115. Centers for Disease Control and Prevention. Emergency Preparedness and Response. Ricin: Treatment Overview for Clinicians. Available at https://emergency.cdc.gov/agent/ricin/clinicians/treatment.asp. Last accessed August 16, 2023.

116. U.S. Department of Health and Human Services Office of Public Health Emergency Preparedness. Response to a Ricin Incident: Guidelines for Federal, State, and Local Public Health and Medical Officials. Washington, DC: Department of Health and Human Services; 2006.

117. U.S. Army Medical Research and Material Command. USAMRIID Begins Clinical Trial of New Vaccine to Protect Against Ricin Toxin. Available at https://mrdc.health.mil/index.cfm/media/news_releases/2011/ricin_toxin_vaccine_trial_begins. Last accessed August 16, 2023.

118. O'Hara JM, Brey RN 3rd, Mantis NJ. Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice. Clin Vaccine Immunol. 2013;20(6):789-794.

119. Soligenix. Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine. Available at https://www.prnewswire.com/news-releases/soligenix-receives-additional-niaid-funding-to-advance-development-of-heat-stable-ricin-vaccine-300476933.html. Last accessed August 16, 2023.

120. Soligenix, Inc. Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax in Nonhuman Primate Survival after Ricin Challenge. Available at https://www.prnewswire.com/news-releases/soligenix-announces-publication-demonstrating-positive-correlates-of-protection-with-rivax-in-non-human-primate-survival-after-ricin-challenge-301706790.html. Last accessed August 16, 2023.

121. Brey RN III, Mantis NJ, Pincus SH, Vitetta ES, Smith LA, Roy CJ. Recent advances in the development of vaccines against. Ricin.Hum Vaccin Immunother. 2016;12(5):1196-1201.

122. Centers for Disease Control and Prevention. Emergency Preparedness and Response. Available at https://emergency.cdc.gov. Last accessed August 16, 2023.

123. Association for Professionals in Infection Control and Epidemiology. Available at https://apic.org/professional-practice/emergency-preparedness. Last accessed August 16, 2023.

124. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Commun Disord Q. 2003;4(2):78-85.